Efonidipine

Drugbox
IUPAC_name = 2-(phenyl-(phenylmethyl)amino)ethyl 5-(5,5-dimethyl-2-oxo-1,3-dioxa-2λ5-phosphacyclohex-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate

---

CAS_number = 111011-63-3
CAS_supplemental =
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem = 119171
DrugBank =
chemical_formula =
C=34 | H=38 | N=3 | O=7 | P=1
molecular_weight = 631.65 g/mol
smiles = CC1=C(C(C(=C(N1)C)P2(=O)OCC(CO2)(C)C)C3=CC(=CC=C3) [N+] (=O) [O-] )C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status = Rx-only
routes_of_administration = Oral

Efonidipine (INN) is a dihydropyridine calcium channel blocker marketed by Shionogi & Co. of Japan. It was launched in 1995, under the brand name Landel.

It has also been studied in atherosclerosiscite journal |author=Toyoda K, Kitahara M, Yamashita T, "et al" |title= [Effect of efonidipine hydrochloride (NZ-105), a new dihydropyridine calcium antagonist, on the experimental atherosclerosis in cholesterol-fed rabbits] |language=Japanese |journal=Nippon Yakurigaku Zasshi |volume=103 |issue=5 |pages=231–9 |year=1994 |month=May |pmid=8188119 |doi= |url=] and acute renal failure.cite journal |author=Shudo C, Masuda Y, Sugita H, Tanaka S, Tomita K |title=Effects of efonidipine hydrochloride (NZ-105), a new calcium antagonist, against acute renal failure in rats |journal=Gen. Pharmacol. |volume=25 |issue=7 |pages=1451–8 |year=1994 |month=November |pmid=7896060 |doi= |url=]

References

* [http://www.shionogi.co.jp/med/kihon/img/pdf/LND.pdf Landel ランデル] (PDF) Shionogi & Co. April 2005.